Peptides DB
Research-centric peptide and protocol reference hub

SS-31 record · updated 17h ago

Healing & recoveryMetabolic & appetiteGrade A · human clinicalResearch use only
All 32 studiesJump to the evidenceCompare
What is SS-31 used for?

SS-31, also known as Elamipretide, is a peptide that has garnered attention for its potential role in mitochondrial protection and its implications in various health conditions, particularly those involving oxidative stress and mitochondrial dysfunction.

How it works: Mitochondrial-targeting peptide that stabilizes cardiolipin

Primarily researched for · Healing & recoveryRoute · Intravenous injection

Development stage

where SS-31 sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 22 registered trials. It describes the research record, not a recommendation.

Identity
NameSS-31
Chain length—
Molecular weight639.8 Da
FormulaC32H49N9O5
Structure typeNot established
ClassMetabolic
Research levelPreclinical
Discovered byAdded before provenance tracking · 2025

Mass and formula from PubChem CID 11764719. No verified residue count for this compound.

Pharmacology
MechanismMitochondrial-targeting peptide that stabilizes cardiolipin
RouteIntravenous injection
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 28, 2026. How this works →
Research stats
Total studies32
Human / animal / cellular20 / 2 / 2
Highest trial phasePreclinical
Years covered2010–2026
Latest study5d ago
Publication history
20102026
Research funding
29,011 NIH projects · $27.3M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

32 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Diagnostic performance of Xpert MTB/RIF Ultra assay for tuberculosis in stool specimens among adult presumptive TB patients in a generalized HIV epidemic setting
FindingSensitivity of Xpert-Ultra assay in stool specimen was 90.32% (95% CI, 74.25% to 97.96%)
Human2026Full text read0.80
Mirusha virus: A novel sand fly-borne phlebovirus with evidence of neutralizing antibodies in humans and dogs in Kosovo.
FindingNeutralizing antibodies detected in dogs (2.0%) and humans (0.8%) in Kosovo.
Human2026Full text read0.80
The clinical significance of exploring concurrent nephropathy in patients with primary renal malignancies.
FindingAll-cause mortality 19.4% vs. 0%, p=0.007.
Human2026Full text read0.80
Statistical analysis plan for the ‘Pharyngeal electrical stimulation for acute stroke dysphagia trial’ (PhEAST) (ISRCTN98886991)
FindingNot reported in abstract.
review2026Partial text0.50
Use of nicotine replacement therapy to reduce children’s exposure to second-hand smoke in the home: Findings of a pilot randomised controlled trial conducted in Scotland
FindingMedian PM 2.5 concentrations reduced in the intervention group by -36μg/m 3.
Human2026Full text read0.80
Cardiovascular and autonomic responses to transcutaneous spinal cord stimulation combined with activity-based therapy after chronic spinal cord injury: An exploratory study from the MACHINE trial
FindingNot reported in abstract.
Human2026Full text read0.80
Optimising the prevention, detection and management of diabetes distress in adults with type 1 diabetes: Feasibility study protocol (D-stress feasibility study)
FindingNot reported in abstract.
Human2026Full text read0.70
Epidemiology of frailty, multimorbidity, and disability: a cross-sectional study of mid-aged and older adults in The Gambia, Zimbabwe and South Africa
FindingOverall mean HRQoL utility score was 0.829 ± 0.107.
Human2026Full text read0.80
Parent-mediated interventions versus usual care in children with autism: A systematic review with meta-analysis and Trial Sequential Analysis
FindingMD = −0.88; 95% confidence interval −2.92 to 1.15; p = 0.05, 4 trials, N = 353, low certainty.
review2026Full text read0.80
Classical driver mutations are not associated with metachronous lesion risk in patients undergoing post-polypectomy surveillance following removal of conventional adenomas in a bowel screening setting
FindingMutation frequency in index adenomas was not associated with metachronous lesions (p=0.901).
Human2026Full text read0.80
Genetic, Microbial, and Lifestyle Correlates of Adolescent Anxiety: A Pilot Cross-Sectional Study of SLC6A4 Genotype and the Oral Microbiome
FindingSS genotype predominated in both cohorts (68% [17/25] in Cohort 1; 100% [31/31] in Cohort 2).
Human2026Full text read0.80
Subfoveal Choroidal Thickness After Combined Pars Plana Vitrectomy and 360° Encircling Scleral Buckling for Primary Rhegmatogenous Retinal Detachment: A Descriptive Swept-Source OCT Analysis
FindingMean BCVA improved from logMAR 1.0 to 0.3 (P < .001).
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching SS-31 will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much SS-31 is discussed should be drawn from it.

Articles mentioning SS-31